Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
STAT3 inhibitor
C188 is a selective STAT3 inhibitor that disrupts STAT3 SH2/pY-peptide binding and inhibits IL-6-mediated STAT3 phosphorylation, with an IC50 of 20 µM. This compound effectively prevents the nuclear-to-cytoplasmic translocation of STAT3, thereby promoting apoptosis in breast cancer cell lines exhibiting constitutive STAT3 activation. C188 demonstrates potent biological activity with EC50 values of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively, highlighting its potential applications in cancer research. -
STAT3 Inhibitor
LY5 is a potent inhibitor of STAT3, exhibiting an IC50 of 0.5 μM. It induces apoptosis and effectively inhibits STAT3 phosphorylation, demonstrating significant antitumor activity in vivo. This compound is utilized in cancer research to explore the mechanisms of STAT3-related signaling pathways and their implications in tumorigenesis. -
STAT3 Inhibitor
HJC0123 is a potent STAT3 inhibitor that effectively suppresses the proliferation of hepatic stellate cells while inducing cell cycle arrest and apoptosis. It reduces STAT3 phosphorylation, nuclear translocation, and transcriptional activity, leading to increased IL-6 production and inhibition of Smad2/3 phosphorylation, along with down-regulation of SOCS3. HJC0123 serves as a valuable tool for investigating liver fibrosis and related pathways. -
STAT3 Inhibitor
STAT3-IN-38 is a selective inhibitor of the signal transducer and activator of transcription 3 (STAT3) protein, exhibiting a KD value of 45.33 µM. By binding to the SH2 domain of STAT3, it effectively inhibits phosphorylation at the pTyr705 site, leading to the downregulation of downstream genes such as Survivin and Mcl-1. This compound has demonstrated the ability to block cell-cycle progression and induce apoptosis in colorectal cancer cells, making it a valuable tool for cancer research and therapeutic development. -
IKK/STAT3 Dual Inhibitor
ACHP is a selective IκB kinase (IKK) and STAT3 dual inhibitor, demonstrating potent inhibitory activity with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. It effectively disrupts the STAT3 signaling pathway, leading to cancer cell cycle arrest and apoptosis. Additionally, ACHP exhibits significant anti-inflammatory properties in preclinical models, such as the mouse ear edema model. This compound is a valuable tool for research in anti-inflammatory and anti-cancer studies, including applications in multiple myeloma and leukemia. -
HDAC3/p-STAT3 Inhibitor
1-Stearoyl-sn-glycero-3-phosphocholine is an inhibitor of histone deacetylase 3 (HDAC3) and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3). This compound has demonstrated the ability to induce apoptosis and exhibits significant anticancer activity in chronic myelogenous leukemia (CML) K562 cells. It serves as a valuable tool for researchers investigating the therapeutic potential of HDAC inhibitors in cancer treatment. -
STAT3/JAK Inhibitor
Brevilin A is a potent inhibitor of the STAT3/JAK signaling pathway, with an IC50 value of approximately 10.6 μM for STAT3. It exhibits anti-tumor properties and effectively inhibits the proliferation of cancer cells. Additionally, Brevilin A has been shown to induce both apoptosis and autophagy, making it a valuable tool for cancer research and therapeutic investigations. -
Stat5a/b Inhibitor
IST5-002 is a selective inhibitor of Stat5a and Stat5b, with IC50 values of 1.5 μM and 3.5 μM, respectively. This compound effectively disrupts the transcriptional activity of Stat5 proteins, inducing apoptosis in prostate cancer and chronic myeloid leukemia (CML) cells. IST5-002 is suitable for research applications focused on understanding the role of Stat5 in cancer progression and therapeutic targeting in prostate cancer and CML. -
STAT3 Inhibitor
Danvatirsen is an antisense oligonucleotide that specifically inhibits STAT3, a transcription factor involved in cell survival and proliferation. This compound reduces cell viability and promotes apoptosis in leukemia cell lines, while downregulating the expression of endogenous STAT3 and its downstream target genes. Additionally, Danvatirsen effectively diminishes proliferation and tumorigenicity in models of neuroblastoma and lymphoma. In vivo studies demonstrate its capacity to inhibit tumor growth rates in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen is applicable in research focused on lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and neuroblastoma. -
STAT3 Inhibitor
HP590 is a potent, orally active inhibitor of STAT3, demonstrating an IC50 of 27.8 nM for STAT3 luciferase activity and 24.7 nM for ATP inhibition. This compound exhibits significant anti-proliferative effects on gastric cancer cells and effectively induces apoptosis. HP590 serves as a valuable research tool for investigating the role of STAT3 in cancer biology and potential therapeutic interventions. -
STAT3 Signal Inhibitor
STAT3-IN-12 is a potent inhibitor of the STAT3 signaling pathway, effectively blocking IL-6 induced JAK/STAT3 activation. This compound exhibits significant anti-cancer activity by inhibiting cell growth, reducing migration, promoting apoptosis, and inducing cell cycle arrest. STAT3-IN-12 is particularly relevant for research applications in cancers such as hepatocellular carcinoma (HCC) and esophageal carcinoma. -
STAT3 Phosphorylation Inhibitor
Tetramethylcurcumin is a selective inhibitor of STAT3 phosphorylation, targeting Janus kinase 2 and the Src homology-2 domain of STAT3. This compound demonstrates significant anti-inflammatory and anti-cancer properties, making it a valuable tool for research into cancer biology and inflammatory pathways. Its ability to modulate key signaling events provides insight into therapeutic strategies for diseases driven by aberrant STAT3 activity. -
STAT3 Inhibitor
STAT3-IN-11 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), specifically targeting the phosphorylation at Tyr705. This compound downregulates the phosphorylation of downstream genes such as Survivin and Mcl-1, while leaving upstream tyrosine kinases like Src and JAK2 unaffected. By inducing apoptosis in cancer cells, STAT3-IN-11 presents potential as a valuable tool for research in cancer therapeutics and the development of effective STAT3 inhibitors. -
AKR1C1/JAK2/STAT3/NF-κB Inhibitor
Zingiberen Newsaponin is a potent inhibitor of the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. This steroid saponin compound demonstrates significant anti-hepatocellular carcinoma (HCC) activity by promoting cancer cell apoptosis through the induction of oxidative stress, as evidenced by the upregulation of ROS and MDA levels. Additionally, Zingiberen Newsaponin mitigates cerebral ischemia-reperfusion injury by reducing pro-inflammatory cytokines and enhancing superoxide dismutase (SOD) activity, thereby protecting neuronal cells. Furthermore, it has been shown to induce platelet aggregation, broadening its application in cardiovascular research. -
STAT3-SH2 Domain Inhibitor
STAT3-SH2 Domain Inhibitor 1 specifically targets the Src Homology 2 (SH2) domain of STAT3, exhibiting a Kd value of 1.57 μM. This compound effectively inhibits STAT3 signaling and transcriptional activation, leading to apoptosis in gastric cancer cells. It serves as a valuable tool for researching mechanisms of cancer progression and potential therapeutic strategies targeting the STAT3 pathway. -
STAT3 Inhibitor
8-Epixanthatin is a STAT3 inhibitor derived from Xanthium chinese Mill. It effectively inhibits STAT3 activation, leading to the induction of apoptosis in cancer cells. This compound demonstrates notable anti-tumor activity, making it a valuable tool for research applications focused on cancer biology and therapeutic development. -
STAT3 Inhibitor
WB436B is a selective inhibitor of STAT3, targeting STAT3-Tyr705 phosphorylation and modulating the expression of downstream STAT3 target genes. This compound exhibits significant cytotoxicity against pancreatic cancer cells while promoting apoptosis. In preclinical mouse models, WB436B has been shown to suppress tumor growth and metastasis, leading to an extended survival rate in tumor-bearing subjects. This makes WB436B a valuable tool for research in cancer biology and therapeutic development. -
STAT3 Inhibitor
HJC0416 hydrochloride is a potent inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that exhibits enhanced anticancer properties compared to Stattic. This compound has demonstrated significant biological activity against breast cancer, making it a promising candidate for cancer research applications. Its oral bioavailability and efficacy highlight its potential as a valuable tool for investigating STAT3-related pathways in oncology. -
STAT3 Inhibitor
SC99 is a selective inhibitor of the STAT3 pathway, exerting its effects through the inhibition of JAK2. By binding to the ATP-binding pocket of JAK2, SC99 effectively prevents the phosphorylation of both JAK2 and STAT3, while sparing other kinases linked to STAT3 signaling. SC99 demonstrates significant biological activity, including the inhibition of platelet activation and aggregation, as well as potent anti-myeloma and anti-thrombotic effects, making it a valuable tool for research in cancer and cardiovascular studies. -
STAT3 Inhibitor
LLL3 is a potent STAT3 inhibitor that effectively impedes the dimerization and phosphorylation of STAT3, thereby blocking its translocation into the nucleus. This mechanism leads to reduced expression of STAT3-dependent genes, including those encoding Bcl-xL and cyclin D1. Moreover, LLL3 has been shown to induce growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells through the activation of the caspase pathway. This reagent is valuable for investigating cancers associated with persistent STAT3 activation. -
STAT5b Inhibitor
Pomstafib-2 is a potent and selective inhibitor of STAT5b, a transcription factor involved in various signaling pathways. This compound reduces the expression of phosphorylated STAT5b (pSTAT5b) and promotes apoptotic processes in cells. Pomstafib-2 is valuable for studying STAT5b-related biological functions and developing therapies targeting STAT5b-driven malignancies. -
JAK2/STAT3/NF-κB Inhibitor
Reticuline acts as a JAK2/STAT3 and NF-κB signaling pathway inhibitor, displaying notable anti-inflammatory properties. It effectively downregulates the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6 while also reducing the phosphorylation levels of JAK2 and STAT3. Additionally, Reticuline demonstrates potential cardiovascular effects, making it a valuable tool for research in inflammation and cardiovascular studies. -
JAK2/STAT3 Inhibitor
SD-1029 is a selective JAK2/STAT3 inhibitor that impedes the phosphorylation of JAK2, thereby obstructing STAT3 activation. By inhibiting STAT3 nuclear translocation, SD-1029 serves as a valuable tool for studying the JAK2/STAT3 signaling pathway. This compound is relevant in research applications involving cancer, autoimmune disorders, and other diseases associated with dysregulated STAT3 activity. -
JAK2/STAT3 Pathway Inhibitor
WP1193 is a potent inhibitor of the JAK2/STAT3 signaling pathway. It effectively suppresses the phosphorylation of both JAK2 and STAT3, leading to a decrease in the expression of key stem cell markers such as CD133 and c-myc. This compound is valuable for research into glioblastoma and other cancers associated with aberrant activation of the JAK2/STAT3 pathway. -
JAK/STAT Inhibitor
JAK-STAT-IN-1 is a selective inhibitor of the JAK-STAT signaling pathway. This compound exhibits potent inhibitory activity, making it a valuable tool in the investigation of autoimmune disorders. Its specificity for JAK-STAT modulation facilitates research into the underlying mechanisms of inflammation and immune response regulation. -
Multi-kinase Inhibitor
Debio 0617B is a multi-kinase inhibitor that targets key kinases involved in the regulation of STAT3/STAT5 signaling, including JAK, SRC, ABL, and class III/V receptor tyrosine kinases. This compound effectively reduces the maintenance and self-renewal of primary human acute myeloid leukemia (AML) CD34+ stem/progenitor cells. Additionally, Debio 0617B has demonstrated efficacy in preclinical models of STAT3-driven solid tumors, making it a valuable tool for cancer research and therapeutic development. -
PTPN2/1 Dual Inhibitor
PTPN2/1-IN-4 is a potent dual inhibitor of PTPN1 and PTPN2, exhibiting IC50 values of 12.8 nM and 5.8 nM, respectively. This compound effectively modulates the IFNγ-JAK-STAT signaling pathway, resulting in enhanced CD8+ T-cell infiltration into tumors. PTPN2/1-IN-4 demonstrates significant anticancer activity, inhibiting tumor growth both as a standalone treatment and in combination with anti-PD-1 antibodies in B16-OVA syngeneic mouse models, making it a valuable tool for cancer research. -
BFAR Inhibitor
iBFAR2 is a selective inhibitor of the BFAR protein, targeting its role in immune modulation. This compound effectively restores the CD8+ tissue-resident memory T (TRM) cell subset, enhancing anti-tumor immunity in solid tumors. iBFAR2 promotes the association between JAK2 and STAT1 as well as the subsequent phosphorylation of STAT1, contributing to its biological activity in cancer research applications. -
JAK2/STAT3 Iinhibitor
HD-2a is a JAK2/STAT3 inhibitor that functions by downregulating circDcbld2 expression in RAW264.7 cells. This compound is valuable for research into the modulation of the JAK2/STAT3 signaling pathway, which is implicated in various inflammatory and autoimmune disorders. HD-2a can aid in the exploration of therapeutic strategies targeting JAK2/STAT3-mediated processes. -
IRS1/2/STAT3 Inhibitor
NT219 is a potent dual inhibitor of insulin receptor substrates 1 and 2 (IRS1/2) and signal transducer and activator of transcription 3 (STAT3). It disrupts IRS1/2 degradation and inhibits STAT3 phosphorylation, impacting essential signaling pathways associated with various oncogenic processes. NT219 is relevant for research applications focused on cancer biology, particularly in understanding the interplay of these critical signaling molecules in tumor progression and resistance. -
STAT3 Inhibitor
STAT3-IN-9 is a selective inhibitor of STAT3, specifically targeting its activation by preventing Tyr705 phosphorylation while leaving STAT1 (Tyr701) unphosphorylated. This compound demonstrates significant biological activity by inducing apoptosis and causing cell cycle arrest at the G2/M phase. It can be effectively utilized in research applications focusing on cancer biology and the role of STAT3 in tumor progression. -
STAT3 Inhibitor
STAT3-IN-53 is a selective inhibitor of STAT3, targeting its SH2 domain with a Kd value of 6.16 μM. This compound effectively suppresses phosphorylation at the Y705 site, thereby inhibiting the IL-6/JAK/STAT3 signaling pathway. By downregulating the transcription and expression of critical oncogenes such as cyclin D1 and c-Myc, STAT3-IN-53 induces cell cycle arrest and promotes apoptosis, demonstrating potential anticancer activity, particularly in colorectal cancer research applications. -
STAT3 Inhibitor
STAT3-IN-18 is a STAT3 inhibitor that selectively targets the JAK2-STAT3 signaling pathway, demonstrating significant anti-proliferative effects in breast cancer cells. This compound promotes apoptotic cell death through the activation of caspase-3 and increases cleaved polyADP-ribose polymerase levels. Additionally, STAT3-IN-18 enhances the maturation and antigen presentation of dendritic cells, while exhibiting favorable safety profiles in vivo, making it a valuable tool for cancer research and immunotherapy studies. -
Miticide/STAT3 Inhibitor
Fluacrypyrim is a potent miticide that functions as a selective inhibitor of the STAT3 signaling pathway. It effectively induces growth arrest and apoptosis in STAT3-dependent cancer cells by significantly decreasing cyclin D1 protein and mRNA levels, leading to G1 cell cycle arrest. Additionally, Fluacrypyrim mitigates irradiation-induced hematopoietic system injury by protecting hematopoietic stem cells from apoptosis. Its analgesic and anti-inflammatory properties are demonstrated through the inhibition of uterine smooth muscle contraction and inflammatory responses, making it a valuable reagent for cancer and inflammation research. -
STAT3 Inhibitor
STAT3-IN-10 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), exhibiting an IC50 value of 5.18 µM. This compound directly interacts with the SH2 domain of STAT3, leading to the induction of apoptosis in cancer cells. STAT3-IN-10 is ideal for research applications focused on elucidating STAT3 signaling pathways and exploring therapeutic strategies for cancer treatment. -
STAT3 Inhibitor
STAT3-IN-50 is a potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) with an IC50 of 0.259 μM. This compound induces apoptosis and effectively inhibits the proliferation of colon and liver cancer cells. It is a valuable tool for research focused on the mechanisms of colon and liver cancers. -
STAT3 Inhibitor
HJC0152 (free base) is a potent and orally active inhibitor of STAT3. It effectively disrupts cell cycle progression and promotes apoptosis, making it a valuable tool for cancer research. Notably, HJC0152 (free base) demonstrates significant suppression of MDA-MB-231 xenograft tumor growth in murine models, indicating its potential utility in studying STAT3-related pathways in cancer. -
STAT5 Inhibitor
BP-1-108 is a selective inhibitor of STAT5, exhibiting a Ki value of 8.3 μM. This compound demonstrates significant anticancer activity by inducing apoptosis in leukemia cells through the inhibition of STAT5 phosphorylation. BP-1-108 is valuable for research applications focusing on acute myeloid leukemia and prostate cancer. -
JAK2/STAT3 Inhibitor
DPP is a Platinum(IV) complex featuring a pterostilbene-derived axial ligand that specifically targets the JAK2/STAT3 signaling pathway. This compound displays significant antiproliferative activity against breast cancer cells by inducing apoptosis through the activation of caspase-3 and cleavage of poly ADP-ribose polymerase. Additionally, DPP enhances the maturation and antigen presentation capability of dendritic cells, demonstrating favorable safety profiles in in vivo studies, making it a promising candidate for cancer immunotherapy research. -
STAT3 Inhibitor
HJC0416 is a potent inhibitor of STAT3, exhibiting significant antiproliferative activity and the ability to induce apoptosis. This compound effectively reduces the expression of phosphorylated STAT3 (Tyr-705) and Cyclin D1 while increasing the levels of cleaved caspase-3. HJC0416 demonstrates promising anti-tumor effects, making it relevant for cancer research applications focused on targeting the STAT3 signaling pathway. -
STAT3 Inhibitor
7-epi-Isogarcinol is a STAT3 inhibitor that exhibits moderate antiproliferative activity. By blocking the STAT3 signaling pathway, it effectively induces apoptosis and inhibits cell migration. This compound is valuable for research applications focused on cancer biology and the exploration of therapeutic strategies targeting STAT3-mediated pathways. -
JAK2/STAT3 Inhibitor
Cernuumolide J is a selective inhibitor of JAK2/STAT3 signaling pathway. It induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of JAK2, STAT3, and Erk, while promoting the phosphorylation of JNK and p38 MAPK. Cernuumolide J exhibits a concentration-dependent growth inhibition of HEL leukemia cells, with an IC50 value of 1.79 μM, making it a valuable compound for research in anti-cancer therapy. -
STAT3 Inhibitor
STAT3-IN-52 is a selective inhibitor of signal transducer and activator of transcription 3 (STAT3) that acts by binding to the phosphorylated tyrosine 705 (pY705) site, with a Ki value of 440 nM. This compound effectively blocks the phosphorylation and dimerization of STAT3, leading to cytotoxic effects in various cancer cell lines, including MDA-MB-231 breast cancer cells (IC50 = 0.7 μM), UW426 medulloblastoma, and BKPC3 pancreatic cancer cells. Additionally, STAT3-IN-52 induces apoptosis, inhibits STAT3 nuclear transport and DNA binding, and downregulates the expression of the STAT3 target gene MMP9, making it a valuable reagent for studying STAT3 dysregulation in cancer research. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
TYK2 Inhibitor
QL-1200186 is a selective, orally active allosteric inhibitor specifically targeting the pseudokinase domain JH2 of tyrosine kinase TYK2, exhibiting an IC50 of 0.06 nM with 164-fold selectivity over TYK1 JH2 (IC50 = 9.85 nM). By stabilizing the TYK2 JH2 conformation, QL-1200186 inhibits the activity of the JH1 catalytic domain and disrupts the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. This compound effectively reduces the production of Th1/Th17-related cytokines and has shown promise in alleviating skin inflammation in Imiquimod-induced psoriasis models, making it relevant for the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE). -
STAT6 Inhibitor
STAT6-IN-7 is a potent inhibitor of STAT6, effectively disrupting the binding of human STAT6 to phosphorylated IL-4 receptor alpha (pIL-4Rα) with an IC50 value of 0.28 μM. Its mechanism of action makes it a valuable tool in the study of inflammatory and allergic diseases, aiding researchers in elucidating the role of STAT6 in these pathological conditions. -
STAT6 Inhibitor
STAT6-IN-9 is a selective inhibitor of Signal Transducer and Activator of Transcription 6 (STAT6), demonstrating an EC50 value of 4 nM. This compound effectively interferes with STAT6 activation driven by the IL-13-IL-13 receptor/IL-4 receptor signaling pathway. Additionally, STAT6-IN-9 inhibits CCL17 secretion with an IC50 of 4.6 nM. It is a valuable tool for investigating chronic inflammatory diseases associated with STAT6 dysregulation, including allergies, asthma, and chronic obstructive pulmonary disease. -
STAT6 Inhibitor
STAT6-IN-10 is a potent inhibitor of signal transducer and activator of transcription 6 (STAT6), exhibiting an EC50 of 0.002 μM. This compound effectively inhibits the secretion of CCL17 in peripheral human whole blood with an IC50 of 0.095 μM, making it a valuable tool for studying inflammatory responses. STAT6-IN-10 is applicable in research focused on dermatological and respiratory conditions, providing insights into therapeutic interventions targeting these pathways. -
STAT6 Inhibitor
STAT6-IN-3 is a potent STAT6 inhibitor designed to selectively target the SH2 domain of STAT6, exhibiting a high binding affinity with an IC50 value of 0.04 μM. This compound is valuable in studying inflammatory processes, particularly in disorders such as asthma, by providing insights into the modulation of STAT6 signaling pathways. Researchers can utilize STAT6-IN-3 to explore its effects on cytokine signaling and immune response regulation. -
STAT3 Inhibitor
SI-109 is a potent inhibitor of the STAT3 SH2 domain, demonstrating an inhibitory constant (Ki) of 9 nM. This compound effectively reduces the transcriptional activity of STAT3 with an IC50 value of 3 μM. SI-109 is utilized in research applications involving antitumor activity and has been instrumental in the development of PROTAC STAT3 degrader SD-36, an important tool in targeted protein degradation studies.
